Search alternatives:
point decrease » point increase (Expand Search)
mean decrease » a decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), teer decrease (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
5 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
point decrease » point increase (Expand Search)
mean decrease » a decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), teer decrease (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
5 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
-
261
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
262
-
263
-
264
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
265
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
266
-
267
-
268
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
269
-
270
-
271
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
272
-
273
-
274
-
275
-
276
-
277
-
278
-
279
-
280